Identification

Name
Ketazolam
Accession Number
DB01587
Type
Small Molecule
Groups
Approved
Description

Ketazolam is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Ketazolam is not approved for sale in the United States or Canada.

Structure
Thumb
Synonyms
  • Ketazolam
  • U-28774
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Loftran Cap 30mgCapsule30 mgOralSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1992-12-311996-09-12Canada
International/Other Brands
Anseren (Novartis) / Ansieten (Ivax) / Ansietil (Medicamenta Ecuatoriana, Ecuador) / Atenual (Tecnofarma) / Marcen (Vegal) / Sedatival F.P. (Recalcine) / Sedavital (Farmindustria) / Sedotime (Faes) / Solatran (GlaxoSmithKline) / Unakalm (Tecnifar)
Categories
UNII
92A214MD7Y
CAS number
27223-35-4
Weight
Average: 368.814
Monoisotopic: 368.092770127
Chemical Formula
C20H17ClN2O3
InChI Key
PWAJCNITSBZRBL-UHFFFAOYSA-N
InChI
InChI=1S/C20H17ClN2O3/c1-13-10-18(24)23-12-19(25)22(2)17-9-8-15(21)11-16(17)20(23,26-13)14-6-4-3-5-7-14/h3-11H,12H2,1-2H3
IUPAC Name
14-chloro-4,10-dimethyl-2-phenyl-3-oxa-7,10-diazatricyclo[9.4.0.0²,⁷]pentadeca-1(11),4,12,14-tetraene-6,9-dione
SMILES
CN1C2=C(C=C(Cl)C=C2)C2(OC(C)=CC(=O)N2CC1=O)C1=CC=CC=C1

Pharmacology

Indication

Ketazolam could be used for the treatment of anxiety. In approved countries, it is indicated for the treatment of anxiety, tension, irritability and similar stress related symptoms.

Structured Indications
Not Available
Pharmacodynamics

Benzodiazepines enhance the effect of the neurotransmitter gamma-aminobutyric acid (GABA), which results in sedative, hypnotic, anxiolytic, anticonvulsant, muscle relaxant and amnesic action. Benzodiazepines bind nonspecifically to benzodiazepine receptors which mediate sleep, affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.

Mechanism of action

Benzodiazepines share a similar chemical structure and their effects in humans are mainly produced by the allosteric modification of a specific kind of neurotransmitter receptor, the GABAA receptor, which increases the conductance of this inhibitory channel; this results in the various therapeutic effects as well as adverse effects of benzodiazepines. Binding of benzodiazepines to this receptor complex promotes binding of GABA, which in turn increases the conduction of chloride ions across the neuronal cell membrane. This increased conductance raises the membrane potential of the neuron resulting in inhibition of neuronal firing. In addition, different GABAA receptor subtypes have varying distributions within different regions of the brain and therefore control distinct neuronal circuits. Hence, activation of different GABAA receptor subtypes by benzodiazepines may result in distinct pharmacological actions.

TargetActionsOrganism
ATranslocator protein
agonist
Human
AGamma-aminobutyric acid receptor subunit alpha-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit beta-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit gamma-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit delta
potentiator
Human
AGamma-aminobutyric acid receptor subunit epsilon
potentiator
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Ketazolam breaks down in the blood to diazepam which breaks down to demoxepam which breaks down to desmethyldiazepam.

Route of elimination

Diazepam and its metabolites are excreted mainly in the urine, predominantly as their glucuronide conjugates.

Half life

26-200 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include somnolence, confusion, coma, and diminished reflexes. Respiration, pulse and blood pressure should be monitored.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Ketazolam is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Ketazolam is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Ketazolam is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Alfaxalone.Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Ketazolam.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ketazolam.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Ketazolam can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Ketazolam is combined with Amisulpride.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ketazolam.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Ketazolam is combined with Amperozide.Experimental
AprepitantThe serum concentration of Ketazolam can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ketazolam.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Ketazolam.Approved
AtazanavirThe metabolism of Ketazolam can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Ketazolam can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Ketazolam is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Azaperone.Investigational, Vet Approved
AzelastineKetazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Ketazolam is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Ketazolam.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Ketazolam is combined with Benperidol.Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ketazolam is combined with Benzyl alcohol.Approved
BoceprevirThe metabolism of Ketazolam can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Ketazolam can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ketazolam can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ketazolam is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ketazolam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Ketazolam is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Ketazolam is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ketazolam.Approved, Investigational
BuprenorphineKetazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ketazolam.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Ketazolam is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Ketazolam is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Ketazolam.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ketazolam.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ketazolam.Approved
CanertinibThe risk or severity of adverse effects can be increased when Ketazolam is combined with Canertinib.Investigational
CarbamazepineThe metabolism of Ketazolam can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Ketazolam.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Ketazolam is combined with Carisoprodol.Approved
CeritinibThe serum concentration of Ketazolam can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Ketazolam.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ketazolam.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ketazolam.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Ketazolam.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ketazolam.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Chlorphenamine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ketazolam.Approved, Vet Approved
ClarithromycinThe metabolism of Ketazolam can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Ketazolam can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Ketazolam is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Ketazolam is combined with clomethiazole.Investigational
ClonazepamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Ketazolam is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ketazolam.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Ketazolam can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ketazolam.Approved
CobicistatThe metabolism of Ketazolam can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Ketazolam.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ketazolam.Approved, Illicit
ConivaptanThe serum concentration of Ketazolam can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Ketazolam can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ketazolam.Approved
CyclosporineThe metabolism of Ketazolam can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Ketazolam can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ketazolam.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Ketazolam can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Ketazolam can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Ketazolam can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Ketazolam can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ketazolam.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ketazolam.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ketazolam.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ketazolam.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Ketazolam.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ketazolam.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Ketazolam is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Ketazolam is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ketazolam.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ketazolam.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ketazolam.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Ketazolam.Experimental
DihydroergotamineThe metabolism of Ketazolam can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ketazolam.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ketazolam.Experimental, Illicit
DiltiazemThe metabolism of Ketazolam can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Ketazolam is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ketazolam.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ketazolam.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Ketazolam is combined with Doramectin.Vet Approved
DoxycyclineThe metabolism of Ketazolam can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Ketazolam is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved, Illicit
DronedaroneThe metabolism of Ketazolam can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Ketazolam.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ketazolam.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Ketazolam.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Ketazolam is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ketazolam.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Ketazolam is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Ketazolam can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Ketazolam can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Ketazolam is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ketazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ketazolam.Approved
EthanolKetazolam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ketazolam.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ketazolam.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ketazolam.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ketazolam.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Ketazolam.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Ketazolam is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ketazolam.Approved, Illicit, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Ketazolam is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Ketazolam can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ketazolam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ketazolam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Ketazolam.Approved
FluvoxamineThe metabolism of Ketazolam can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Ketazolam can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ketazolam can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Ketazolam can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fospropofol.Approved, Illicit, Investigational
Fusidic AcidThe serum concentration of Ketazolam can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ketazolam.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Ketazolam is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ketazolam.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Ketazolam is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Ketazolam.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Ketazolam.Approved, Illicit, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Ketazolam.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Ketazolam.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ketazolam.Approved
HydrocodoneKetazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketazolam.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved
IdelalisibThe serum concentration of Ketazolam can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Iloperidone.Approved
ImatinibThe metabolism of Ketazolam can be decreased when combined with Imatinib.Approved
IndalpineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Ketazolam can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Ketazolam is combined with Indiplon.Investigational
IsavuconazoniumThe metabolism of Ketazolam can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ketazolam.Approved, Vet Approved
IsradipineThe metabolism of Ketazolam can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Ketazolam can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ketazolam can be increased when it is combined with Ivacaftor.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Ketazolam can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ketazolam.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Ketazolam is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ketazolam.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Ketazolam is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ketazolam.Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Ketazolam.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Ketazolam.Approved
LofentanilThe risk or severity of adverse effects can be increased when Ketazolam is combined with Lofentanil.Illicit
LopinavirThe metabolism of Ketazolam can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Loprazolam.Experimental
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ketazolam.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Lormetazepam.Approved
LovastatinThe metabolism of Ketazolam can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ketazolam.Approved
LuliconazoleThe serum concentration of Ketazolam can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Ketazolam can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ketazolam.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Ketazolam.Illicit, Investigational, Withdrawn
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved, Vet Approved
MebicarThe risk or severity of adverse effects can be increased when Ketazolam is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Ketazolam.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ketazolam.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Ketazolam is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ketazolam.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Ketazolam.Experimental
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Ketazolam.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Ketazolam is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ketazolam.Approved
MethotrimeprazineKetazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ketazolam.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Ketazolam is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Methylecgonine.Experimental
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ketazolam.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ketazolam.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Ketazolam.Approved
MetyrosineKetazolam may increase the sedative activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Ketazolam.Experimental
MifepristoneThe serum concentration of Ketazolam can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Ketazolam is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved, Investigational
MirtazapineKetazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Ketazolam can be decreased when it is combined with Mitotane.Approved
MolindoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Molindone.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ketazolam.Approved
NefazodoneThe metabolism of Ketazolam can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Ketazolam can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Ketazolam can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Ketazolam can be increased when combined with Nevirapine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Ketazolam.Approved, Investigational
NilotinibThe metabolism of Ketazolam can be decreased when combined with Nilotinib.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ketazolam.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ketazolam.Approved, Investigational
OlaparibThe metabolism of Ketazolam can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ketazolam.Approved
OpiumThe risk or severity of adverse effects can be increased when Ketazolam is combined with Opium.Approved, Illicit
OrphenadrineKetazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Ketazolam is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Ketazolam can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ketazolam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ketazolam.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ketazolam.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ketazolam.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ketazolam.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Ketazolam can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ketazolam.Approved
ParaldehydeKetazolam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Ketazolam is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ketazolam.Approved, Vet Approved
PentobarbitalThe metabolism of Ketazolam can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved
PerazineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Perazine.Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Ketazolam.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Ketazolam is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ketazolam.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ketazolam.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Ketazolam is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Ketazolam can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ketazolam is combined with Phenoxyethanol.Approved
PhenytoinThe metabolism of Ketazolam can be increased when combined with Phenytoin.Approved, Vet Approved
PipamperoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Ketazolam is combined with Piritramide.Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ketazolam.Approved
PizotifenThe risk or severity of adverse effects can be increased when Ketazolam is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Ketazolam is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Ketazolam can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleKetazolam may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ketazolam.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Ketazolam.Approved
PrimidoneThe metabolism of Ketazolam can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Ketazolam.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ketazolam.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Ketazolam.Approved, Vet Approved
PropanididThe risk or severity of adverse effects can be increased when Ketazolam is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ketazolam.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ketazolam.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Propoxycaine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Ketazolam is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Ketazolam is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Ketazolam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ketazolam.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Ketazolam is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ramelteon.Approved, Investigational
RanolazineThe serum concentration of Ketazolam can be increased when it is combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ketazolam.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ketazolam.Approved, Withdrawn
RifabutinThe metabolism of Ketazolam can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Ketazolam can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ketazolam can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ketazolam.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ritanserin.Investigational
RitonavirThe metabolism of Ketazolam can be decreased when combined with Ritonavir.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Romifidine.Vet Approved
RopiniroleKetazolam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ketazolam.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Ketazolam.Approved
RotigotineKetazolam may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ketazolam.Approved
SaquinavirThe metabolism of Ketazolam can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ketazolam.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Ketazolam is combined with Sertindole.Approved, Investigational, Withdrawn
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ketazolam.Approved, Vet Approved
SildenafilThe metabolism of Ketazolam can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Ketazolam can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ketazolam can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved
St. John's WortThe serum concentration of Ketazolam can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Ketazolam can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ketazolam.Approved, Investigational
SulfisoxazoleThe metabolism of Ketazolam can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ketazolam.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Ketazolam is combined with Sultopride.Experimental
SuvorexantKetazolam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Ketazolam can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Ketazolam can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ketazolam.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Ketazolam.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tetrodotoxin.Investigational
ThalidomideKetazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ketazolam.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Ketazolam.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ketazolam.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ketazolam.Approved
TiagabineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Ketazolam can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Ketazolam can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Ketazolam is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ketazolam.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ketazolam.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ketazolam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Trichloroethylene.Experimental
TrifluperidolThe risk or severity of adverse effects can be increased when Ketazolam is combined with Trifluperidol.Experimental
TriprolidineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Triprolidine.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Ketazolam.Approved, Experimental
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Ketazolam.Approved, Investigational
VenlafaxineThe metabolism of Ketazolam can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Ketazolam is combined with Veralipride.Experimental
VerapamilThe metabolism of Ketazolam can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Ketazolam is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Ketazolam is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Ketazolam can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Ketazolam is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Ketazolam can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ketazolam.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ziconotide.Approved
ZiprasidoneThe metabolism of Ketazolam can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Zolazepam.Vet Approved
ZolpidemKetazolam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Ketazolam is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ketazolam.Approved
ZotepineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ketazolam.Approved, Investigational
Food Interactions
  • Avoid alcohol
  • Avoid excessive quantities of coffee or tea (caffeine).
  • Avoid taking with grapefruit or grapefruit juice as grapefruit can significantly increase serum levels of this product.
  • Take with food.

References

Synthesis Reference

U.S. Patent 3,575,965.

General References
Not Available
External Links
Human Metabolome Database
HMDB15526
PubChem Compound
33746
PubChem Substance
46507008
ChemSpider
31110
ChEBI
135556
ChEMBL
CHEMBL2104356
PharmGKB
PA164749385
Wikipedia
Ketazolam
ATC Codes
N05BA10 — Ketazolam

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral30 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)174-176U.S. Patent 3,575,965.
Predicted Properties
PropertyValueSource
Water Solubility0.0839 mg/mLALOGPS
logP2.6ALOGPS
logP3.01ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)14.2ChemAxon
pKa (Strongest Basic)-0.89ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area49.85 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity99.78 m3·mol-1ChemAxon
Polarizability36.96 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9965
Blood Brain Barrier+0.9382
Caco-2 permeable+0.7069
P-glycoprotein substrateSubstrate0.7006
P-glycoprotein inhibitor IInhibitor0.6305
P-glycoprotein inhibitor IINon-inhibitor0.8837
Renal organic cation transporterNon-inhibitor0.7534
CYP450 2C9 substrateNon-substrate0.8193
CYP450 2D6 substrateNon-substrate0.8504
CYP450 3A4 substrateSubstrate0.7504
CYP450 1A2 substrateNon-inhibitor0.5878
CYP450 2C9 inhibitorInhibitor0.5154
CYP450 2D6 inhibitorNon-inhibitor0.9257
CYP450 2C19 inhibitorInhibitor0.5938
CYP450 3A4 inhibitorInhibitor0.6037
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.52
Ames testNon AMES toxic0.7228
CarcinogenicityNon-carcinogens0.789
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8992 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9935
hERG inhibition (predictor II)Non-inhibitor0.8687
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0a59-1290000000-7ef8a75bf466c745a728
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
1,4-benzodiazepines
Direct Parent
1,4-benzodiazepines
Alternative Parents
Alpha amino acids and derivatives / Benzene and substituted derivatives / Aryl chlorides / Vinylogous esters / Tertiary carboxylic acid amides / Lactams / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 4 more
Substituents
1,4-benzodiazepine / Alpha-amino acid or derivatives / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Benzenoid / Tertiary carboxylic acid amide / Vinylogous ester / Carboxamide group / Lactam
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Cholesterol binding
Specific Function
Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in l...
Gene Name
TSPO
Uniprot ID
P30536
Uniprot Name
Translocator protein
Molecular Weight
18827.81 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Falchi AM, Battetta B, Sanna F, Piludu M, Sogos V, Serra M, Melis M, Putzolu M, Diaz G: Intracellular cholesterol changes induced by translocator protein (18 kDa) TSPO/PBR ligands. Neuropharmacology. 2007 Aug;53(2):318-29. Epub 2007 Jun 2. [PubMed:17631921]
  3. Vega D, Fernandez D, Echeverria G: Ketazolam. Acta Crystallogr C. 2001 Jul;57(Pt 7):848-50. Epub 2001 Jul 9. [PubMed:11443263]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Blaschke G, Kley H, Muller WE: [Racemation of the benzodiazepines camazepam and ketazolam and receptor binding of enantiomers]. Arzneimittelforschung. 1986 Jun;36(6):893-4. [PubMed:2874815]
  2. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  3. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
  4. Derry JM, Dunn SM, Davies M: Identification of a residue in the gamma-aminobutyric acid type A receptor alpha subunit that differentially affects diazepam-sensitive and -insensitive benzodiazepine site binding. J Neurochem. 2004 Mar;88(6):1431-8. [PubMed:15009644]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB1
Uniprot ID
P18505
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-1
Molecular Weight
54234.085 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
  3. Derry JM, Dunn SM, Davies M: Identification of a residue in the gamma-aminobutyric acid type A receptor alpha subunit that differentially affects diazepam-sensitive and -insensitive benzodiazepine site binding. J Neurochem. 2004 Mar;88(6):1431-8. [PubMed:15009644]
  4. Blaschke G, Kley H, Muller WE: [Racemation of the benzodiazepines camazepam and ketazolam and receptor binding of enantiomers]. Arzneimittelforschung. 1986 Jun;36(6):893-4. [PubMed:2874815]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRG1
Uniprot ID
Q8N1C3
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-1
Molecular Weight
53594.49 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRD
Uniprot ID
O14764
Uniprot Name
Gamma-aminobutyric acid receptor subunit delta
Molecular Weight
50707.835 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRE
Uniprot ID
P78334
Uniprot Name
Gamma-aminobutyric acid receptor subunit epsilon
Molecular Weight
57971.175 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Bertucci C, Wainer IW: Improved chromatographic performance of a modified human albumin based stationary phase. Chirality. 1997;9(4):335-40. [PubMed:9275312]
  2. Brodersen R, Honore B: Drug binding properties of neonatal albumin. Acta Paediatr Scand. 1989 May;78(3):342-6. [PubMed:2545072]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH: In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther. 2001 Mar;296(3):723-35. [PubMed:11181899]
  2. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684]

Drug created on August 29, 2007 09:28 / Updated on November 09, 2017 03:02